Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing
autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and
carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of
melphalan and bendamustine in the setting of autologous transplantation for multiple myeloma
is feasible and safe.